By DengYueMed International Business DivisionToday, DengYueMed shares key commercial insights into China’s EGFR small-molecule targeted therapy market with international buyers and distribution partners. Drawing on the latest publicly available data, we analyzed the sales trends ...Learn More

By DengYueMed International Business DepartmentChronic diseases (Non-Communicable Diseases, NCDs) have become a major global health challenge. According to the World Health Organization (WHO), approximately 41 million people die from chronic diseases each year, accounting for 71% ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More

Antibody–Drug Conjugates (ADCs): Leading the Global Oncology RevolutionAs cancer treatment enters the era of precision and personalization, Antibody–Drug Conjugates (ADCs)—often referred to as “biological missiles”—represent one of the highest frontiers of ...Learn More